May 17, 2019 10:16 AM EDTUpdated May 20, 09:39 AM
Peer Review

Bio­gen ex­ec Paul McKen­zie heads to CSL as COO; Pul­ma­trix CEO re­signs

Kathy Wong

Editor

→ Af­ter Bio­gen’s re­cent cat­a­stro­phe with ad­u­canum­ab, Paul McKen­zie, the com­pa­ny’s EVP for phar­ma­ceu­ti­cal op­er­a­tions and tech­nol­o­gy (and mem­ber of its ex­ec­u­tive com­mit­tee) …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

CBER's deputy di­rec­tor de­parts as staff shake­up con­tin­ues

Blue­bird bio to sell to in­vest­ment funds af­ter strug­gling to make mon­ey from gene ther­a­pies

FDA ap­proves first drug to treat ul­tra-rare lipid stor­age dis­ease

Eli Lil­ly stock­piles $548M of oral weight loss drug ahead of launch

FDA says Ozem­pic, We­govy short­age is over

sponsored

Trust­ed pro­tec­tion: Why the cur­rent meningo­coc­cal vac­ci­na­tion sched­ule shouldn’t change with­out strong ev­i­dence

A service from the Financial Times